Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01920633 · ClinicalTrials.gov registry record
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A clinical trial, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 135
- Enrollment target
NCT01920633 is a clinical trial that has completed, run by Hoffmann-La Roche. The registered enrollment target is 135 participants.
The verdict
NCT01920633 has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 135 participants
- Enrollment target
Study Summary
This is a single visit study in which people with Down syndrome aged 12-30 will attend the clinical center to undergo assessments to evaluate their eligibility for potential enrollment in the future BP27832 Phase II clinical study which will evaluate the efficacy, safety and tolerability of RG1662. Study participants may withdraw from this study at any time and for any reason.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2013-10-31 |
| Est. Completion | 2015-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01920633
The ClinicalTrials.gov registry entry for NCT01920633 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01920633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01920633 about?
NCT01920633 is a clinical study titled "A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)". This is a single visit study in which people with Down syndrome aged 12-30 will attend the clinical center to undergo assessments to evaluate their eligibility for potential enrollment in the future BP27832 Phase II clinical study which will evaluate the efficacy, safety and tolerability of RG1662. ...
What is the current status of trial NCT01920633?
This trial is currently completed. The enrollment target is 135 participants. The study started on 2013-10-31. Estimated completion is 2015-01-31.
Who is sponsoring clinical trial NCT01920633?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.